Voyager goes big, securing multi-billion dollar gene therapy development deal with Neurocrine
The neurological disease outfit helmed by Biogen’s former R&D chief announced a big gene therapy deal Monday, starting #JPM23 with its largest deal to date.
Voyager Therapeutics is once again going after gene therapies with Neurocrine Biosciences. The two teamed up on a large pact in 2019, but the Parkinson’s portion of the tie-up fizzled out in February 2021. The work on Friedreich’s ataxia from that deal remains ongoing.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.